| Literature DB >> 20370596 |
Abstract
This paper deals with aneurysmal disease, primarily when localized in the abdominal aorta. It is based on the Olof Rudbeck lecture 2009. Aneurysm is a localized widening of an artery, and its definition has become an important issue today when the disease is in focus for screening programmes. Aetiology and pathogenesis are still poorly understood, but a genetic component determining the strength of the aortic wall is important, and there is a strong male dominance. Historically, several attempts have been made to treat the disease, but reconstructive treatment has been possible only since 1951, in an increasing number of cases performed endovascularly. By early detection through screening, and thereby the possibility to treat before rupture, it has now become possible to decrease the total mortality from the disease in the population.Entities:
Mesh:
Year: 2010 PMID: 20370596 PMCID: PMC2853783 DOI: 10.3109/03009730903518480
Source DB: PubMed Journal: Ups J Med Sci ISSN: 0300-9734 Impact factor: 2.384
Figure 1.Schematic drawing of the aortic diameter during a lifetime.
Figure 2.Factors influencing the development of an aortic aneurysm.
Figure 3.Sex-specific prevalence of abdominal aortic aneurysm confirmed by necropsy (from Bengtsson et al. 1992 with permission (28)).
Frequency of aneurysms in the abdominal aorta (AAA) in the general male population (ultrasonographic screening).
| Prevalence (%) | ||||||
|---|---|---|---|---|---|---|
| Author | Reference | Country | Attendance rate | Age | Total | > 50 mm |
| Bengtsson | ( | Malmö, Sweden | 75 | 74 | 10.7 | 2.2 |
| Scott | ( | UK | 59 | 65–80 | 7.6 | 1.0 |
| Lederle | (17) | USA | 30 | 50–79 | 4.6 | 0.5 |
| Wanhainen | (27) | Norsjö, Sweden | 91 | 65–75 | 17.3 | 4.8 |
| Wanhainen | Unpublished | Uppsala, Sweden | 84 | 65 | 3.3 | 0.5 |
aNumber attending the screening of those invited (in per cent).
Risk factors for abdominal aortic aneurysm.
| Male gender |
| Age |
| Smoking |
| Family history |
| Occlusive arterial disease |
World Health Organization criteria for surveillance programmes.
The disease should be an important health problem. The disease should have a high prevalence. The biological behaviour must be shown. The surveillance/screening test must have a high sensitivity and specificity. A method of treatment should be available. The screening programme must be cost-effective. |
Substances of interest to analyse whether or not there is a favourable influence on expansion rate of abdominal aortic aneurysms.
| Statins |
| Angiotensin-converting enzyme inhibitors |
| Macrolides |
| Cyclo-oxygenase inhibitors |
| Indomethacin |
| Tetracyclines |
| Vapamycin |
| Doxycycline |
| Roxithromycin |
| Azithromycin |